Medical release archive

AstraZeneca advancing clinical practice in heart failure with unprecedented data and number of simultaneous publications of DELIVER Phase III results

New Tezspire data at ERS International Congress 2022 continue to strengthen profile for a broad population of severe asthma patients

New analyses in real-world setting support the effectiveness of Fasenra in severe eosinophilic asthma

POSEIDON Phase III post-hoc exploratory analyses presented at WCLC 2022

Vaxzevria 73% effective at preventing Omicron-related infections after fourth dose, according to real world evidence study in Thailand

Vaxzevria shown in expert review to provide equally effective protection against COVID-19 hospitalisation and death as mRNA vaccines

AstraZeneca shares data at EASL and ESMO World GI for Imfinzi combinations in patients with liver and biliary tract cancers

PROpel Phase III trial positive results of Lynparza plus abiraterone in 1st-line metastatic castration-resistant prostate cancer published in New England Journal of Medicine Evidence

Bydureon BCise (exenatide prolonged-release) approved in the EU for paediatric patients with type-2 diabetes

First patients dosed in IRIS Phase III trial evaluating Saphnelo in lupus nephritis